Comparative 12-week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real-world multicenter retrospective study.

Today, dermatologists commonly prescribe ustekinumab, secukinumab and ixekizumab in routine clinical practice due to their proven success rate. At this time, real-life comparison between these three treatments is scarce. Our aim was to compare head-to-head the clinical effectiveness and associated reported adverse events (AEs) of ustekinumab, secukinumab and ixekizumab within routine clinical practice.